Company intelligence / Profile preview

Swalife Biotech

Ownership: Private
Development stage: Commercial

Overview

Swalife Biotech focuses on developing products that target DNA damage response pathways, using small molecules derived from plants. Their technology involves isolating polyphenolic and alkaloid compounds with anti-cancer properties.

Therapeutic areas: Oncology
Modalities: Small molecules (polyphenolic and alkaloids)
Industry: Biotech

Drug pipeline

3 assets

Precisor E8

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

RebelBio accelerator program

Beyond the preview

Go deeper on Swalife Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Swalife Biotech.

Explore the full profile